Top of this page
Skip navigation, go straight to the content
Research & Development
UCB's goal is to command a leading position in discovering and developing new therapies to treat patients suffering from severe diseases. With a strong pipeline, our focus is on central nervous system (CNS) disorders and immunology diseases to provide new treatments for specialists and their patients.
Our key features
- Patients are at the heart of all we do, driving our commitment to the treatment of severe diseases
- A focus on two main therapeutic areas: central nervous system (CNS) and immunology
- An attractive late stage pipeline
- An international R&D organisation comprised of UCB New MedicinesTM and UCB Global Projects and Development
- A track record of successful partnerships with both academia and leading drug discovery organisations. Partnership is part of our philosophy
Contact us
Magazine›
-
Strategic partnerships to further strengthen R&D
Strategic partnerships to further strengthen R&D
Posted by Antje Witte, Investor Relations 25-Nov-2011
-
Europe can innovate its way to growth
Europe can innovate its way to growth
Posted by France Nivelle, Global Communications & Change Support 10-Aug-2011
-
An Osteoporosis Odyssey
An Osteoporosis Odyssey
Posted by Antje Witte, Investor Relations 13-Jul-2011
What have bone research, and NASA got in common?
One team approach
Our philosophy is to have a 'one team' approach to drug discovery and development with seamless integration of research, development and commercial colleagues, in a process of continual learning and confirming as we examine our data and capitalise on our knowledge. Our people
